Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients.
Fabian Martin TroschelBenjamin O TroschelMaren KlossJohanna JostNiklas Benedikt PepperAmelie S TroschelRainer G WiewrodtWalter StummerDorothee WiewrodtHans Theodor EichPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2024)
Sarcopenia is a strong risk factor for treatment discontinuation and reduced progression-free survival in glioblastoma patients. We propose that sarcopenic patients should receive intensified supportive care during radiotherapy and during follow-up as well as expedited access to palliative care.